|
Published by: SMI Publishing, Ltd
Published: Jun. 7, 2006
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Tauseef Butt, President, Life Sensors.
- 9.10 MOVING PROTEIN DRUG CANDIDATES FROM DISCOVERY TO DEVELOPMENT
- Biotherapeutics in Wyeth
- The biotech heritage of Wyeth
- Different forms of recombinant protein drugs
- Protein expression in E. coli, thioredoxin fusion system
- CHO cell expression system
- Process improvement
- Dr Zhijian Lu, Assistant Director, Biotherapeutics Expression & Purification, Wyeth Research.
- 9.50 SUMO TAGS AND DIFFICULT TO EXPRESS PROTEINS
- SUMO fusion technology platform for prokaryotic and eukaryotic expression and purification
- SUMOylation system, nature’s design for tagging and chaperoning proteins in cells
- SUMO family of tags remarkably enhance protein expression and facilitate purification
- No parallel system for producing proteins with desired N-termini
- Chaperone properties of SUMO system to produce native structures
- Designer tags for solubilisation of challenging proteins
- Dr Tauseef Butt, President, Life Sensors.
- 10.30 Morning Coffee
- 11.30 INSECT CELL EXPRESSION SYSTEMS
- Baculovirus expression systems: decreasing time to data without sacrificing scale-up and reproducibility
- Baculovirus instead of E.coli expression as first line trials for structural research support
- Elimination of cloning bottleneck using gene synthesis collaboration
- Multi-paralleled expression screening of constructs on an E.coli timescale
- 4 days form DNA to expression results
- 21 days from DNA to Biomass, including plaque purification
- Reproducible scale-up without the use of viral titres
- Dr Joey Studts, Principal Scientist & Head, Protein Resources, Boehringer Ingelheim .
- 12.10 A SIMPLE TECHNOLOGY FOR THE SIMULTANEOUS EXPRESSION OF 4 TANDEM GENES
- Novel Technologies
- Expression of multiple proteins from one promoter or multiple proteins with different promoters
- Protein expressed at desired levels in the same cell
- Eliminating the need for co-transfection of multiple plasmids
- Expression of 1-4 different inserts from one vector
- Ultimate flexibility: removal and replacement of single or multiple inserts from a construct
- Dr Jon Chestnut, Research & Development, Invitrogen Ltd .
- 12.50 Networking Lunch
- 2.20 HIGH-THROUGHPUT PROTEIN PRODUCTION SYSTEM AT SMALL / INTERMEDIATE SCALE
- Secreted (mammalian-expressed) protein pipeline
- Summary of general pipeline system and mechanistics
- Lessons learned
- A discussion of issues regarding tech-transfer
- Dr Thierry Battle, Biotechnology Services Manager, Serono Pharmaceutical Research Institute.
- 3.00 BACULOVIRUS PRODUCTION AND PROTEIN EXPRESSION
- Developing biological and automated tools
- An overview of traditional methods
- New technologies to overcome the labour intensive and technically demanding nature of baculovirus production and protein expression
- Development of the baculoworkstation
- Manual vs automated procedures
- The advantages of the baculoworkstation
- Dr Kevin Richards, Senior scientist, NextGen Sciences Ltd.
- 3.40 Afternoon Tea
- 4.00 PRODUCTION OF SOLUBLE MAMMALIAN PROTEINS IN ESCHERICHIA COLI
- Identification of protein features that correlate with successful expression
- Cloning strategy
- Comparison of tags and host strains for E. coli expression
- Production pipeline to supply antigens for antibody production
- A case study: the immunoglobulin superfamily (IgSF)
- Dr Michael Dyson, Project Leader, Protein Expression, Wellcome Trust Sanger Institute.
- 4.40 HIGH THROUGHPUT VALUATION OF PROTEIN EXPRESSION CLONES
- Description of our method and comparison with alternative approaches
- E. coli protein expression and protein purification in microtitre plates
- Comparison of micro-scale and large-scale protein production for crystallisation and structural analysis
- Data management of large numbers of clones
- Dr Konrad Bussow, Team Leader, Protein Structure Factory, Max Planck Institute for Molecular Genetics.
- 5.20 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Scott Patterson, Senior director, Medical Sciences, Amgen.
- 9.10 BIOMARKERS - THE NEW AGE OF DIAGNOSTICS AND DRUG DISCOVERY?
- The application of biomarkers to early clinical development
- Identifying the unmet medical need
- Techniques and tools
- New developments
- Potential pitfalls in biomarker analysis
- Dr Scott Patterson, Senior director, Medical Sciences, Amgen.
- 9.50 PROTEIN PROCESSING
- Improving protein solubility and its impact on protein research
- Greater protein stability
- Minimise losses during purification
- Obtain full structural data without interference with the protein
- Simpler protein refolding
- Better protein assays and analysis
- Dr Paul Docherty, Buiness Development, Novexin.
- 10.30 Morning Coffee
- 10.55 HIGH THROUGHPUT PROTEIN PURIFICATION
- New technologies
- Overview of high throughput protein purification methods and hardware
- Purity vs yield
- Time and cost implications
- The future of protein purification
- Mr David Bannister, Senior Protein Purification Scientist, Cambridge Antibody Technology.
- 11.30 PROTEIN PURIFICATION AND CRYSTALLISATION SUCCESS RATES
- Parallel and sequential processing
- High throughput protein purification methods used to produce proteins for crystallisation trials
- Analytical methods used in-process and for end products
- Nanovolume Crystallisation®
- The use of databases for tracking
- Examples
- Lessons learnt
- Dr Robert Wynands, Director, Structural Biology, Takeda San Diego, Inc.
- 12.40 Networking Lunch
- 1.40 STRATEGIES FOR SUPPLYING PROTEINS FOR STRUCTURAL STUDIES
- Case studies and approaches employed at Pfizer
- Protein production - overcoming challenges
- Experiences with alternative expression systems
- Protein purification and affinity tags
- Mutagenisis strategies
- Case studies
- Dr Stephen Irving, Senior Principal Scientist, Pfizer.
- 2.20 PROTEIN REFOLDING
- A case study
- Current strategies
- Optimising conditions
- Automated and parallel approaches
- Functional analysis
- Challenges and future perspectives
- Dr Stefan Schmidt, Team Leader, Protein Science, AstraZeneca.
- 3.00 THE NEXT FRONTIER IN PROTEIN ANALYSIS
- LabChip Electrophoresis
- Time to result and quantitative data are vital in protein process decisions
- Quality of decisions are based on quality of data
- Microfluidic assays are the new SDS-PAGE
- Automated analysis is key to data reproducibility and laboratory throughput
- Dr Bahram Fathollahi, Research & Development Engineer, Microfluidics, Caliper Life Sciences.
- 3.40 Afternoon Tea
- 4.40 FRAGMENT-BASED DRUG DISCOVERY
- Strategies and challenges in optimising weak fragment hits
- Why screen fragments?
- NMR-based approaches for fragment library screening
- Challenges for crystallography of fragment hits
- Building leads from fragments
- Embedding fragment-based approaches into the big pharma environment
- Case studies from AstraZeneca
- Dr Alex Breeze, Head, NMR Structural Biology, AstraZeneca.
- 5.20 Chairman’s Closing Remarks and Close of Day One
AbstractWith the ever-expanding therapeutic market, research and development is fundamental for improving current treatments and the design of protein based drugs of the future. With the variety of protein expression systems rapidly evolving, there is more pressure to harvest larger, purer quantities of product. Furthermore, a vast number of biomarker discovery studies have recently been embarked upon, requiring new, more efficient methods to identify and analyse proteins involved in disease populations with the aim to lead to novel diagnostic tools and treatments.
SMi’s Global Protein Summit, 2006 will be an excellent opportunity to hear about the latest developments from world leaders, bringing together expertise in effective protein expression, purification, identification and functional analysis and how to overcome the common and not so common pitfalls. Discussing research and manufacturing activities in both academia and industry, this unique opportunity will provide genuine opportunities of networking. A must attend event for all those involved in protein research and production.
Hear contributions from leading industry experts, including:
- Dr Scott Patterson, Senior Director, Medical Sciences, Amgen Inc
- Dr Zhijian Lu, Assistant Director, Biotherapeutics Expression & Purification, Wyeth
- Dr Stephen Irving, Senior Principal Scientist, Pfizer
- Dr Joey M. Studts, Principal Scientist & Head, Protein Resources, Boehringer-Ingelheim
- Dr Thierry Battle, Biotechnology Services Manager, Serono Pharmaceutical Research Institute
- Dr Tauseef Butt, President, Life Sensors
- Dr Robert Wynands, Director, Structural Biology, Takeda San Diego
- Dr Alex Breeze, Head, NMR Structural Biology, AstraZeneca
- Dr Michael Dyson, Project Leader, Protein Expression, The Wellcome Trust Sanger Institute
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
